Recent research has found that using psychedelic substances has been linked to better physical health. However, the cause of the link between the two is still not clear.
The study’s corresponding author, Otto Simonsson, stated that while a lot of research on classic psychedelics had shown the various mental health benefits they possessed, little was known about how these psychedelics may impact long-term physical health outcomes. Simonsson, who is from the University of Oxford, added that he was curious to find out.
For purposes of their research, the researchers examined data collected from 171,766 individuals who responded to surveys conducted between 2015–2018 by the National Survey on Drug Use and Health. The survey, which is conducted every year, measures the prevalence of mental health and substance use issues in the United States.
In addition to gathering information on body mass index and self-assessed overall health, the survey asked respondents if they had used psychedelic drugs before. The survey found that nearly 14% of participants admitted to having used a classic psychedelic substance at least once. Classic psychedelics include DMT, psilocybin, mescaline and LSD.
The researchers then controlled for various variables, including the use of other drugs, education, household income, sex and age, which led them to the discovery that individuals who admitted to having used a psychedelic drug had better self-reported health than respondents who had never used these psychedelics. Additionally, they found that respondents who had used psychedelics also had considerably lower odds of being obese or overweight.
In the research, which was published in the “Journal of Psychopharmacology,” Simonsson stated that the findings proposed that lifetime use of classic psychedelic was linked to various physical health outcomes, adding that caution should still be exercised. Specifically, caution should apply on the correlation nature of the data the researchers had collected as it limits the results’ interpretation. Researchers who had conducted prior studies on the subject believed that the transcendent experience one underwent while on classic psychedelics could bring about long-term changes in an individual’s health behavior, which promotes better physical health.
However, those researchers did note that it was also possible that individuals who had better physical health would be more likely to consume psychedelics as compared to individuals with worse physical health.
Simonsson noted that the primary question was still whether psychedelics affected physical health outcomes in the long term positively, stating that this needed to be tested in randomized, placebo-controlled, double-blind trials. He added that the research team was open to partnerships with other research teams.
What is becoming increasingly clear are the benefits of psychedelic substances in the treatment of mental health conditions, and XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is hard at work developing medicinal products that are primarily intended for the European market.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.